FI112169B - Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi - Google Patents

Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi Download PDF

Info

Publication number
FI112169B
FI112169B FI940674A FI940674A FI112169B FI 112169 B FI112169 B FI 112169B FI 940674 A FI940674 A FI 940674A FI 940674 A FI940674 A FI 940674A FI 112169 B FI112169 B FI 112169B
Authority
FI
Finland
Prior art keywords
preservative
injection
solution
human
infusion
Prior art date
Application number
FI940674A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI940674L (fi
FI940674A0 (fi
Inventor
Fritz Demmer
Werner Gruber
Heinrich Woog
Gerhard Winter
Hans-Joerg Markl
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6438353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112169(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of FI940674L publication Critical patent/FI940674L/fi
Publication of FI940674A0 publication Critical patent/FI940674A0/fi
Application granted granted Critical
Publication of FI112169B publication Critical patent/FI112169B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI940674A 1991-08-15 1994-02-14 Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi FI112169B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4126983A DE4126983A1 (de) 1991-08-15 1991-08-15 Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126983 1991-08-15
EP9201822 1992-08-10
PCT/EP1992/001822 WO1993003744A1 (de) 1991-08-15 1992-08-10 Verfahren zur herstellung von humanproteinhaltigen, konservierten arzneimitteln für infusions- oder injektionszwecke

Publications (3)

Publication Number Publication Date
FI940674L FI940674L (fi) 1994-02-14
FI940674A0 FI940674A0 (fi) 1994-02-14
FI112169B true FI112169B (fi) 2003-11-14

Family

ID=6438353

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940674A FI112169B (fi) 1991-08-15 1994-02-14 Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi

Country Status (25)

Country Link
US (2) US5503827A (cs)
EP (2) EP0528313A1 (cs)
JP (1) JP3670660B2 (cs)
KR (1) KR100263282B1 (cs)
AT (1) ATE145138T1 (cs)
AU (2) AU678756B2 (cs)
CA (1) CA2115348C (cs)
CZ (1) CZ284853B6 (cs)
DE (2) DE4126983A1 (cs)
DK (1) DK0607156T3 (cs)
ES (1) ES2094923T3 (cs)
FI (1) FI112169B (cs)
GE (1) GEP19981289B (cs)
GR (1) GR3022037T3 (cs)
HU (1) HU227421B1 (cs)
IL (1) IL102775A (cs)
MX (1) MX9204636A (cs)
NO (1) NO309844B1 (cs)
RU (1) RU2091068C1 (cs)
SG (1) SG66226A1 (cs)
SK (1) SK281910B6 (cs)
TW (1) TW351677B (cs)
UA (1) UA26343C2 (cs)
WO (1) WO1993003744A1 (cs)
ZA (1) ZA926122B (cs)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
JP3541054B2 (ja) * 1994-04-21 2004-07-07 ユニ・チャーム株式会社 使い捨ておむつ
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
EP0837883B1 (en) * 1995-06-07 2005-08-10 Chiron Corporation Method of solubilizing, purifying, and refolding protein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU1750997A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
WO1997026011A1 (en) * 1996-01-19 1997-07-24 Eli Lilly And Company Obesity protein formulations
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
DK0917879T3 (da) * 1997-11-22 2002-11-04 Roche Diagnostics Gmbh Forbedret fremgangsmåde til stabilisering af proteiner
JP2001525341A (ja) * 1997-11-28 2001-12-11 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性ヘッジホッグタンパク質変異体、その調製方法及び医薬への適用
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6776983B1 (en) 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6207718B1 (en) 1998-08-07 2001-03-27 Ontogeny, Inc. Pharmaceutical compositions containing hedgehog protein
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
BR0012674A (pt) 1999-07-22 2002-09-17 Aventis Pharma Inc Formulações farmacêuticas preservadas
CZ302750B6 (cs) * 1999-07-22 2011-10-19 Aventis Holdings Inc. Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
RU2218151C2 (ru) * 2001-12-11 2003-12-10 Замаев Ильяс Амсудинович Способ консервации растворов лекарственных средств
ES2615484T3 (es) * 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
ATE553747T1 (de) * 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7851433B2 (en) * 2003-08-13 2010-12-14 Novartis Vaccines And Diagnostics, Inc. Method of purifying TFPI and TFPI analogs
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
KR101149454B1 (ko) * 2004-08-24 2012-05-25 간가와 겐지 생리활성 펩티드의 액상 제제
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
DK2197919T3 (da) * 2007-08-27 2014-07-07 Ratiopharm Gmbh Flydende formulering af g-csf-konjugat
PT2076243E (pt) 2007-08-27 2014-12-05 Ratiopharm Gmbh Formulação líquida de g-csf
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2412385A1 (en) * 2008-02-08 2012-02-01 BioGeneriX AG Liquid formulation of FSH
US8120369B2 (en) 2009-03-02 2012-02-21 Harris Corporation Dielectric characterization of bituminous froth
JP6125141B2 (ja) 2009-09-25 2017-05-10 株式会社アールテック・ウエノ 点眼剤
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
HUE052280T2 (hu) 2014-12-03 2021-04-28 Csl Behring Ag Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
WO2018187590A1 (en) * 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3106073A1 (de) * 1981-02-19 1982-08-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU648509B2 (en) * 1989-07-14 1994-04-28 Wyeth Holdings Corporation Stable vaccine compositions containing interleukins
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Also Published As

Publication number Publication date
NO940499L (no) 1994-02-14
AU710768B2 (en) 1999-09-30
CZ284853B6 (cs) 1999-03-17
SK281910B6 (sk) 2001-09-11
NO309844B1 (no) 2001-04-09
KR100263282B1 (ko) 2000-08-01
IL102775A0 (en) 1993-01-31
UA26343C2 (uk) 1999-08-30
AU678756B2 (en) 1997-06-12
HU227421B1 (en) 2011-05-30
EP0607156A1 (de) 1994-07-27
FI940674L (fi) 1994-02-14
CZ28794A3 (en) 1994-08-17
RU94016163A (ru) 1996-08-10
AU1633997A (en) 1997-05-22
JP3670660B2 (ja) 2005-07-13
IL102775A (en) 1999-12-22
CA2115348C (en) 2007-07-17
ZA926122B (en) 1994-02-14
HU9400416D0 (en) 1994-05-30
GR3022037T3 (en) 1997-03-31
TW351677B (en) 1999-02-01
EP0607156B1 (de) 1996-11-13
SG66226A1 (en) 1999-07-20
DK0607156T3 (da) 1997-04-07
SK14894A3 (en) 1994-11-09
DE4126983A1 (de) 1993-02-18
HUT67379A (en) 1995-04-28
DE59207523C5 (de) 2006-11-16
DE59207523D1 (de) 1996-12-19
WO1993003744A1 (de) 1993-03-04
ATE145138T1 (de) 1996-11-15
CA2115348A1 (en) 1993-03-04
NO940499D0 (no) 1994-02-14
AU2409492A (en) 1993-03-16
FI940674A0 (fi) 1994-02-14
EP0528313A1 (de) 1993-02-24
JPH06510031A (ja) 1994-11-10
US5503827A (en) 1996-04-02
RU2091068C1 (ru) 1997-09-27
MX9204636A (es) 1993-02-01
US6303113B1 (en) 2001-10-16
ES2094923T3 (es) 1997-02-01
GEP19981289B (en) 1998-05-01

Similar Documents

Publication Publication Date Title
RU2091068C1 (ru) Способ получения консервированного, содержащего протеин человека, лекарственного средства для инъекционного или инфузионного введения
EP0909564B1 (en) Erythropoietin solution preparation stabilized with amino acids
EP1180368B1 (en) Freeze dried hgf preparations
JP5941496B2 (ja) 成長ホルモン製剤
EP2501367B1 (en) Formulation for HGH and RHIGF-1 combination
KR100236393B1 (ko) 사람성장호르몬을 함유하는 의약제제
JP3143470B2 (ja) ポリペプチド含有の皮下または筋肉内投与用医薬組成物
JP3927248B2 (ja) Ｈｇｆ凍結乾燥製剤
CN1132626C (zh) 稳定化的生长激素制剂和其制备方法
EP1641486B1 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
KR20050015445A (ko) 알부민을 함유하지 않는 에리스로포이에틴 제제
KR880002037B1 (ko) 인터페론 조성물 및 이의 제조방법
RU2025126931A (ru) СОСТАВЫ, ВКЛЮЧАЮЩИЕ ВАРИАНТЫ ПОЛИПЕПТИДА ActRIIa
WO2022034545A1 (en) Etelcalcetide formulations for parenteral use
US20070128231A1 (en) Erythropoietin solution formulation
HK1093012B (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

MA Patent expired